|Cornerstone Announces New Analysis Shows Lower Mortality Rates; MelApp for iPhone Application Receives Record Downloads|
|By Staff and Wire Reports|
|Thursday, 26 January 2012 19:28|
Cornerstone Therapeutics (NASDAQ: CRTX) announced a new analysis published in the eFirst Pages section of the Pediatrics website reporting significant benefits in mortality rate and the need for redosing when treating neonatal respiratory distress syndrome with Cornerstone's CUROSURF® (poractant alfa) Intratracheal Suspension(1).
The objective of the independently performed meta-analysis was to compare the efficacy of CUROSURF versus Survanta® (beractant) and Infasurf® (calfactant) with respect to clinical outcomes among preterm infants with RDS. The analysis was led by Neetu Singh, M.D., at Dartmouth Hitchcock Medical Center.
Named one of the "Top 10 Apps That Could Save Your Life" in the Jan. 22, 2012 issue of Parade Magazine, Health Discovery Corporation (OTC:HDVY), the molecular diagnostics company that launched MelApp in July 2011, the first SVM-based image analysis iPhone app for melanoma risk assessment; is pleased to announce it has received a record number of downloads in the days following the article. The national exposure resulted in an increase of more than 3,100 percent in daily downloads since the article was issued.
"We are beyond excited about the recognition MelApp received in Parade Magazine and the success that we have seen as a result of the coverage," said Stephen D. Barnhill, M.D., chairman and CEO of Health Discovery Corporation. "It's always great to be recognized for MelApp by industry peers, but to be included in such a powerful article in a highly-reputable national publication such as Parade is quite an honor."
Launched in July 2011, MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze an uploaded image. Using the camera feature of their iPhone, iPad or iPod Touch, MelApp users can capture an image of their mole or freckle to be analyzed; use the app's zoom and/or tracing functionality to accurately identify the outline of their mole; then upload it to MelApp's system for assessment. The app was validated using an image database licensed from Johns Hopkins University Medical Center and can deliver a risk analysis of user's photographed skin lesions within seconds. In addition, MelApp can use the iPhone GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical follow-up.
Arrhythmia Research Technology, Inc. (NYSE Amex: HRT) announced that its Board of Directors declared a quarterly cash dividend of $0.03 per share.
With combined sales from the top HIV treatment on the market and several other drugs, Gilead Sciences leads the antiviral market, according to healthcare market research publisher Kalorama Information, closely followed by Bristol-Myers Squibb (NYSE:BMY), Roche (PINK:RHHBY) and Merck (NYSE:MRK).
CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products using patented technologies for use in healthcare, safety and security markets, today announced the appointment of Jason Bradley Terrell, M.D. as medical director of the company.
FMI Holdings Ltd. (formerly Forbes Medi‐Tech Inc.) (OTCBB:FMTIF) ("FMI" or the "Company") today announced that its board of directors has authorized the Company to take such actions as are required to liquidate and dissolve the corporation.
Medicure Inc. (TSX VENTURE:MPH)(PINKSHEETS:MCUJ), a specialty pharmaceutical company, today reported its second quarter 2012 financial results.